The Janssen Pharmaceutical Companies of Johnson & Johnson’s ENSEMBLE Vaccine Trial

Henry Ford Health System is a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical vaccine trial, ENSEMBLE trial. This vaccine trial will evaluate the safety and efficacy (effectiveness) of Janssen’s investigational COVID-19 vaccine candidate, also known as Ad26.COV2.S.  

This vaccine requires only a single dose. This is an international trial including participants across the United States and other countries that will enroll approximately 60,000 adults.

If you are over age 40 and interested in volunteering, please fill out the Pre-screening Form. The trial is filling quickly, so if you are interested in volunteering, do not delay. Completing the form doesn't obligate you to take part, but it tells the Henry Ford research team you’re interested. If there is space available, the research team may contact you.

The research team at Henry Ford Health System is asking people in Southeast Michigan to consider enrolling in the vaccine trial, especially if they are at high risk for coming in contact with COVID-19 in their daily lives, or if they have a higher chance of becoming sick if they do get the virus. Volunteers are especially needed who are:

  • African-American 
  • Latino/Latina 
  • Over age 60 years
  • Individuals with chronic health conditions
  • Nursing home workers and residents
  • First responders, such as police officers, fire fighters, and EMS
  • Essential, critical infrastructure workers, such as transportation, power, water, and hospital healthcare workers

However, the ENSEMBLE trial is open to anyone over age 40 who is not immunocompromised. 

Thank you for your support of Henry Ford Health System and our groundbreaking research. Your interest in participating in a vaccine trial makes a difference for all who have been impacted by COVID-19.

Henry Ford Health System is registered and posted as a Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research trial participant on identifier: NCT04505722